Clinical trial
A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus
NCT01030952 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- February 28, 2011
- Enrollment
- 103 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.